The Pulmonx® assessment platforms – Chartis® and StratX – uniquely enable physicians to select the patients most likely to respond to treatment with the Zephyr Endobronchial Valve. It is the only minimally invasive treatment that enables physicians to predict success.

We have success rates of more than 90% when we select the right patients. Prof. Dr. med. Felix Herth, FCCP – UniversitätsKlinikum Heidelberg – Germany
If you focus on selecting the right patient and place these valves properly, we can significantly improve outcomes. Dr. Pallav Shah, MD – Royal Brompton & Harefield London – United Kingdom

Selection criteria for the Zephyr valve therapy includes patients who:

  • Are breathless despite optimal medication (e.g., mMRC ≥2)
  • Have higher obstruction (FEB, <50% predicted)
  • Have suspected emphysema/hyperinflation (e.g., RV >175% predicted)

 

Please refer to the Instructions for Use for a complete listing of indications, contraindications, warnings and precautions.